Evercore ISI analyst Gavin Clark-Gartner has maintained their bullish stance on ABBV stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gavin Clark-Gartner has given his Buy rating due to a combination of factors tied to AbbVie’s current performance and longer‑term growth drivers. He notes that the latest financial results and guidance were solid overall, with key franchises like Skyrizi and Rinvoq delivering upside versus expectations and several neurology assets, including CGRP therapies and Vyalev/tavap, now collectively targeting multibillion‑dollar peak sales. While oncology was softer and aesthetics tracked in line, the aggregate portfolio still supports strong earnings, and he views the company’s 2026 and 2027 targets as achievable or beatable.
At the same time, he acknowledges investor concerns about intensifying competition in inflammatory bowel disease, particularly from Tremfya and other emerging entrants after 2028, but argues that the market is already pricing in much of this risk. He highlights AbbVie’s IBD combination programs as a crucial strategy to sustain growth into the early 2030s, with potential launches around 2030–2032 to defend and expand share. Maintaining a robust long‑term Skyrizi forecast and incorporating updated guidance into his model, he arrives at a 2026 EPS estimate of $14.59 (or $12.62 adjusted for Skyrizi royalties) and a revised $228 price target, which he views as offering sufficient upside to justify an Outperform/Buy recommendation.